Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 120486
Published online Aug 15, 2026. doi: 10.4251/wjgo.120486
Published online Aug 15, 2026. doi: 10.4251/wjgo.120486
Table 4 Comparison of the incidence of adverse reactions between the two groups of patients, n (%)
| Type of adverse reaction | Observation group (n = 50) | Control group (n = 50) | χ2 | P value |
| Dizziness | 12 (24.00) | 8 (16.00) | 0.98 | 0.322 |
| Lethargy | 10 (20.00) | 6 (12.00) | 1.15 | 0.284 |
| Peripheral edema | 8 (16.00) | 4 (8.00) | 1.72 | 0.190 |
| Constipate | 6 (12.00) | 18 (36.00) | 8.57 | < 0.001 |
| Nausea and vomiting | 4 (8.00) | 14 (28.00) | 7.81 | 0.005 |
| Itchy skin | 3 (6.00) | 5 (10.00) | 0.54 | 0.463 |
| Overall incidence | 23 (46.00) | 21 (42.00) | 0.16 | 0.689 |
- Citation: Wang XY, Wang ZD, Kan K, Guo XX. Impact of combined pregabalin and multimodal analgesia on cancer pain and quality of life in advanced colorectal cancer. World J Gastrointest Oncol 2026; 18(8): 120486
- URL: https://www.wjgnet.com/1948-5204/full/v18/i8/120486.htm
- DOI: https://dx.doi.org/10.4251/wjgo.120486